Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Gynecology

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 61 articles: HTML format

Single Articles

December 2025
1. KASIUS JC, Kildal W, Vrede SW, Askautrud HA, et al
   Surgical stage in the era of molecular profiling of endometrial cancer.
   Eur J Cancer. 2025;233:116164.
   PubMed     Abstract available
   
   
   
2. LIN Y, Chen X, Chen W, Sun Y, et al
   Letter to the editor Re: Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
   Eur J Cancer. 2025;233:116163.
   PubMed    
   
   
   November 2025
3. SECCHI M, Signorelli M, Rulli E, Maruccio M, et al
   Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis.
   Eur J Cancer. 2025;232:116116.
   PubMed     Abstract available
   
   
   
4. PUJOL P, Roca L, Lortholary A, Lasset C, et al
   Letrozole to prevent breast cancer in postmenopausal women with BRCA1/2 mutations (LIBER study).
   Eur J Cancer. 2025;231:116101.
   PubMed     Abstract available
   
   
   October 2025
5. LOMBAERS MS, Reijnen C, Sprik A, Bretova P, et al
   ENDORISK-2: A personalized Bayesian network for preoperative risk stratification in endometrial cancer, integrating molecular classification and preoperative myometrial invasion assessment.
   Eur J Cancer. 2025;231:116058.
   PubMed     Abstract available
   
   
   
6. RAMESH-KUMAR D, Sanchez-Castillo A, Soler M, Martin-Tejera JF, et al
   Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models.
   Eur J Cancer. 2025;230:116040.
   PubMed     Abstract available
   
   
   September 2025
7. LI H, Sui T, He Q
   Letter Re: ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
   Eur J Cancer. 2025;230:115803.
   PubMed    
   
   
   
8. RAMOS-CASALLAS A, Cardona-Mendoza A, Perdomo-Lara SJ, Rico-Mendoza A, et al
   Performance evaluation of machine learning models in cervical cancer diagnosis: Systematic review and meta-analysis.
   Eur J Cancer. 2025;229:115768.
   PubMed     Abstract available
   
   
   August 2025
9. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
   Response to Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2- a multinational population-based cohort study.
   Eur J Cancer. 2025;228:115743.
   PubMed    
   
   
   
10. ZHANG Y, Kang Q, Qu R
    Letter Re: Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;228:115742.
    PubMed    
    
    
    
11. WANG L, Chang Q, Li M
    Letter Re: Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly (ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;228:115740.
    PubMed    
    
    
    
12. CAPASSO I, Perrone E, Loverro M, Giannarelli D, et al
    Focal lymphovascular space invasion: Friend or foe? A large retrospective analysis on stage I endometrioid endometrial carcinomas.
    Eur J Cancer. 2025;228:115736.
    PubMed     Abstract available
    
    
    
13. ALPERT A, Shirron N, Shirman Y, Goshen-Lago T, et al
    Deciphering the proteomic landscape of pregnancy-associated colorectal cancer.
    Eur J Cancer. 2025;228:115718.
    PubMed     Abstract available
    
    
    
14. PERRONE E, Distefano E, Palmieri E, Giannarelli D, et al
    ENDOESTRO score: Where is the dark side? Evaluation of estrogen receptor expression cutoff in endometrial cancer molecular classification, an ambispective study.
    Eur J Cancer. 2025;227:115686.
    PubMed     Abstract available
    
    
    July 2025
15. HARDIE AN, Wenzel HHB, Schnack TH, Van der Aa MA, et al
    Oncological outcomes after radical hysterectomy followed by adjuvant (chemo)radiation or no further treatment in women with cervical cancer FIGO 2018 IB2-IIA2 - A multinational population-based cohort study.
    Eur J Cancer. 2025;227:115664.
    PubMed     Abstract available
    
    
    
16. BLONS H, Abdelli J, Landman S, Taly V, et al
    Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.
    Eur J Cancer. 2025;225:115534.
    PubMed     Abstract available
    
    
    June 2025
17. CAPOZZI VA, Perrone E, Scarpelli E, Tarantino V, et al
    Exploring isolated tumor cells entity in endometrial cancer.
    Eur J Cancer. 2025;225:115586.
    PubMed     Abstract available
    
    
    
18. COLEMAN RL, Fleming GF, Brady MF, Swisher EM, et al
    Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results.
    Eur J Cancer. 2025;225:115587.
    PubMed     Abstract available
    
    
    
19. LEDERMANN JA, Oza AM, Lorusso D, Aghajanian C, et al
    Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
    Eur J Cancer. 2025;225:115584.
    PubMed     Abstract available
    
    
    May 2025
20. PORTER JM, Jin C, Churchman M, Croy I, et al
    Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer.
    Eur J Cancer. 2025;224:115522.
    PubMed     Abstract available
    
    
    
21. WANG H, Wang N
    Letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 May 19:115515. doi: 10.1016/j.ejca.2025.115515.
    PubMed    
    
    
    
22. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Corrigendum to "Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage ovarian cancer: A retrospective cohort study" [Eur J Cancer 222 (2025) 115472].
    Eur J Cancer. 2025;223:115492.
    PubMed    
    
    
    
23. HOLLIS RL, Herrington CS, Gourley C
    Response to letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025 May 5:115491. doi: 10.1016/j.ejca.2025.115491.
    PubMed    
    
    
    
24. KARABUGA B, Baskurt K, Mammadzada N, Sutcuoglu O, et al
    Letter RE: Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high-grade serous carcinoma.
    Eur J Cancer. 2025 May 4:115490. doi: 10.1016/j.ejca.2025.115490.
    PubMed    
    
    
    April 2025
25. FIORE M, Ljevar S, Raut CP, Personeni G, et al
    Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study.
    Eur J Cancer. 2025;222:115474.
    PubMed     Abstract available
    
    
    
26. STEVENTON L, Nicum S, Chambers P, Man K, et al
    Risk of secondary myelodysplastic syndromes and acute myeloid leukaemia following poly(ADP-ribose) polymerase inhibitor treatment for advanced-stage recurrent ovarian cancer: A retrospective cohort study in England.
    Eur J Cancer. 2025;222:115472.
    PubMed     Abstract available
    
    
    
27. LIU W, Yang Y
    Letter re: The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025 Apr 25:115446. doi: 10.1016/j.ejca.2025.115446.
    PubMed    
    
    
    
28. ONAL C, Elmali A, Demirhan B, Guler OC, et al
    Letter comments on: "Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial".
    Eur J Cancer. 2025 Apr 22:115448. doi: 10.1016/j.ejca.2025.115448.
    PubMed    
    
    
    
29. EMINOWICZ G, Vaja S, Hackshaw A, McCormack M, et al
    Response to letter Re: Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025 Apr 22:115449. doi: 10.1016/j.ejca.2025.115449.
    PubMed    
    
    
    
30. BIGANZOLI G, Isnaldi E, Richard F, Marano G, et al
    Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial.
    Eur J Cancer. 2025;222:115438.
    PubMed     Abstract available
    
    
    
31. MAGATON IM, Blondeaux E, Hamy AS, Linn S, et al
    Assisted reproductive technology in young BRCA carriers with a pregnancy after breast cancer: An international cohort study.
    Eur J Cancer. 2025;222:115434.
    PubMed     Abstract available
    
    
    
32. LEIBETSEDER A, Berghoff AS
    Response to letter commenting on "Association of pregnancy with tumour progression in patients with glioma".
    Eur J Cancer. 2025 Apr 9:115411. doi: 10.1016/j.ejca.2025.115411.
    PubMed    
    
    
    
33. DANG C, Liu P, Yu X
    Letter Re: Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025 Apr 4:115410. doi: 10.1016/j.ejca.2025.115410.
    PubMed    
    
    
    March 2025
34. MAENG CH, Han K, Hong JY, Park JH, et al
    Association between premature menopause and the risk of biliary tract cancer: A nationwide cohort study.
    Eur J Cancer. 2025;220:115387.
    PubMed     Abstract available
    
    
    
35. EMINOWICZ G, Vaja S, Gallardo D, Kent C, et al
    Induction chemotherapy followed by chemoradiation in locally advanced cervical cancer: Quality of life outcomes of the GCIG INTERLACE trial.
    Eur J Cancer. 2025;220:115375.
    PubMed     Abstract available
    
    
    
36. SIITONEN H, Joensuu J, Savolainen-Peltonen H, Gissler M, et al
    Update of the impact of menopausal hormone therapy on breast cancer risk.
    Eur J Cancer. 2025;220:115340.
    PubMed     Abstract available
    
    
    
37. CAPASSO I, Perrone E, Duranti S, Giannarelli D, et al
    Are all mismatch repair deficient endometrial cancers created equal? A large, retrospective, tertiary center experience.
    Eur J Cancer. 2025;220:115344.
    PubMed     Abstract available
    
    
    February 2025
38. VILLACAMPA G, Eminowicz G, Navarro V, Carita L, et al
    Immunotherapy and PARP inhibitors as first-line treatment in endometrial cancer: A systematic review and network meta-analysis.
    Eur J Cancer. 2025;220:115329.
    PubMed     Abstract available
    
    
    
39. STEGER K, Fiegl H, Feroz B, Leitner K, et al
    Differences in immunogenicity of TP53-mutated cancers with low tumor mutational burden (TMB) A study on TP53mut endometrial-, ovarian- and triple-negative breast cancer.
    Eur J Cancer. 2025;219:115320.
    PubMed     Abstract available
    
    
    
40. VERGOTE I, Copeland LJ, Van Gorp T, Laenen A, et al
    Tumor Treating Fields therapy in platinum-resistant ovarian cancer: Results of the ENGOT-ov50/GOG-3029/INNOVATE-3 pivotal phase 3 randomized study.
    Eur J Cancer. 2025;219:115306.
    PubMed     Abstract available
    
    
    
41. HASEGAWA K, Nishio S, Yamamoto K, Fujiwara H, et al
    Tegafur-uracil maintenance chemotherapy post-chemoradiotherapy for cervical cancer: Randomized trial.
    Eur J Cancer. 2025;219:115304.
    PubMed     Abstract available
    
    
    
42. HOLLIS RL, Churchman M, Grimes GR, Meynert AM, et al
    Somatic BRCA1/2 mutations are associated with a similar survival advantage to their germline counterparts in tubo-ovarian high grade serous carcinoma.
    Eur J Cancer. 2025;219:115299.
    PubMed     Abstract available
    
    
    January 2025
43. LI Z, Peng J, Zhang B, Zhao C, et al
    The prognostic and clinical significance of substantial lymphovascular space invasion in early-stage endometrial carcinoma.
    Eur J Cancer. 2025;218:115258.
    PubMed     Abstract available
    
    
    
44. LEIBETSEDER A, Mair MJ, Serra AS, Spiro Z, et al
    Association of pregnancy with tumour progression in patients with glioma.
    Eur J Cancer. 2025;218:115259.
    PubMed     Abstract available
    
    
    
45. OAKNIN A, Monk BJ, de Melo AC, Kim HS, et al
    Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
    Eur J Cancer. 2025;216:115146.
    PubMed     Abstract available
    
    
    December 2024
46. MARME F, Krieghoff-Henning EI, Kiehl L, Wies C, et al
    Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.
    Eur J Cancer. 2024;216:115199.
    PubMed     Abstract available
    
    
    
47. QUESADA S, Penault-Llorca F, Matias-Guiu X, Banerjee S, et al
    Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics.
    Eur J Cancer. 2024;215:115169.
    PubMed     Abstract available
    
    
    
48. HEMMINGSEN CH, Kjaer SK, Hjorth S, Norby U, et al
    Maternal use of hormonal contraception and risk of childhood leukemia: A Scandinavian population-based cohort study.
    Eur J Cancer. 2024;215:115168.
    PubMed     Abstract available
    
    
    November 2024
49. MATIAS-GUIU X, Lax S, Raspollini MR, Palacios J, et al
    FIGO 2023 staging for endometrial cancer, when, if it is not now?
    Eur J Cancer. 2024;213:115115.
    PubMed     Abstract available
    
    
    October 2024
50. WENZEL HHB, Schnack TH, Van der Aa MA, Jensen PT, et al
    Risk factors for lymph node metastasis in women with FIGO 2018 IA cervical cancer with a horizontal spread of > 7 mm.
    Eur J Cancer. 2024;212:115063.
    PubMed     Abstract available
    
    
    
51. GIANNOPOULOS S, Naeem S, Nasioudis D, Gossner G, et al
    Value of surgical lymph node assessment for patients with vulvar melanoma.
    Eur J Cancer. 2024;210:114303.
    PubMed     Abstract available
    
    
    September 2024
52. BIZZARRI N, Querleu D, Ramirez PT, Dostalek L, et al
    Survival associated with the use of sentinel lymph node in addition to lymphadenectomy in early-stage cervical cancer treated with surgery alone: A sub-analysis of the Surveillance in Cervical CANcer (SCCAN) collaborative study.
    Eur J Cancer. 2024;211:114310.
    PubMed     Abstract available
    
    
    
53. VULSTEKE C, Chambers SK, Perez MJR, Chan JK, et al
    Tolerability of the niraparib individualized starting dose in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy.
    Eur J Cancer. 2024;208:114157.
    PubMed     Abstract available
    
    
    August 2024
54. BOLLINO M, Geppert B, Lonnerfors C, Masback A, et al
    Prevalence and size of pelvic sentinel lymph node metastases in endometrial cancer.
    Eur J Cancer. 2024;209:114265.
    PubMed     Abstract available
    
    
    July 2024
55. FASCHING PA, Hack CC, Nabieva N, Maass N, et al
    Prognostic impact of selection criteria of current adjuvant endocrine therapy trials NATALEE and monarchE in postmenopausal HRpos/HER2neg breast cancer patients treated with upfront letrozole.
    Eur J Cancer. 2024;209:114239.
    PubMed     Abstract available
    
    
    
56. SOUTHWORTH E, Thomson JP, Croy I, Churchman M, et al
    Whole exome sequencing reveals diverse genomic relatedness between paired concurrent endometrial and ovarian carcinomas.
    Eur J Cancer. 2024;208:114205.
    PubMed     Abstract available
    
    
    May 2024
57. ROMA C, Esposito Abate R, Sacco A, Califano D, et al
    Harmonization of homologous recombination deficiency testing in ovarian cancer: Results from the MITO16A/MaNGO-OV2 trial.
    Eur J Cancer. 2024;206:114127.
    PubMed     Abstract available
    
    
    April 2024
58. BOLLINO M, Geppert B, Lonnerfors C, Persson J, et al
    A selective anatomically based lymph node sampling can replace a side specific pelvic lymphadenectomy in endometrial cancer with failed sentinel node mapping.
    Eur J Cancer. 2024;204:114049.
    PubMed     Abstract available
    
    
    
59. GRAVBROT N, Weil CR, DeCesaris CM, Gaffney DK, et al
    Corrigendum to "Differentiation of survival outcomes by anatomic involvement and histology with the revised 2023 International Federation of Gynecology and Obstetrics staging system for endometrial cancer" Eur. J. Cancer (201) (April) 2024, 113913.
    Eur J Cancer. 2024 Apr 2:114017. doi: 10.1016/j.ejca.2024.114017.
    PubMed    
    
    
    March 2024
60. TUNINETTI V, Virano E, Salutari V, Ricotti A, et al
    Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
    Eur J Cancer. 2024;203:114039.
    PubMed     Abstract available
    
    
    
61. BOIDOT R, Blum MGB, Wissler MP, Gottin C, et al
    Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.
    Eur J Cancer. 2024;202:113978.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.